The global Bi-Specific Antibodies Therapy market was valued at US$ 3266 million in 2023 and is anticipated to reach US$ 17140 million by 2030, witnessing a CAGR of 26.4% during the forecast period 2024-2030.

Bi-Specific Antibodies Therapy Market

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.

North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.

Report Scope

The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bi-Specific Antibodies Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Bi-Specific Antibodies Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Bi-Specific Antibodies Therapy Market Report

Report Metric	Details
Report Name	Bi-Specific Antibodies Therapy Market
Accounted market size in 2023	US$ 3266 million
Forecasted market size in 2030	US$ 17140 million
CAGR	26.4%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Fragment-Based Antibodies IgG-Based Antibodies
Segment by Application	Cancer Haemophilia Other Non-Cancer Diseases
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie, Lindis Biotech, MacroGenics, Inc, Genmab, Alphamab Co. Ltd, Akeso, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bi-Specific Antibodies Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Bi-Specific Antibodies Therapy Market growing?

Ans: The Bi-Specific Antibodies Therapy Market witnessing a CAGR of 26.4% during the forecast period 2024-2030.

What is the Bi-Specific Antibodies Therapy Market size in 2030?

Ans: The Bi-Specific Antibodies Therapy Market size in 2030 will be US$ 17140 million.

What is the market share of major companies in Bi-Specific Antibodies Therapy Market?

Ans: Global top five manufacturers hold a share over 95%.

What is the Bi-Specific Antibodies Therapy Market share by type?

Ans: In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%.

Who are the main players in the Bi-Specific Antibodies Therapy Market report?

Ans: The main players in the Bi-Specific Antibodies Therapy Market are Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie, Lindis Biotech, MacroGenics, Inc, Genmab, Alphamab Co. Ltd, Akeso, Inc.

What are the Application segmentation covered in the Bi-Specific Antibodies Therapy Market report?

Ans: The Applications covered in the Bi-Specific Antibodies Therapy Market report are Cancer, Haemophilia, Other Non-Cancer Diseases

What are the Type segmentation covered in the Bi-Specific Antibodies Therapy Market report?

Ans: The Types covered in the Bi-Specific Antibodies Therapy Market report are Fragment-Based Antibodies, IgG-Based Antibodies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Fragment-Based Antibodies

1.2.3 IgG-Based Antibodies

1.3 Market by Application

1.3.1 Global Bi-Specific Antibodies Therapy Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Cancer

1.3.3 Haemophilia

1.3.4 Other Non-Cancer Diseases

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Bi-Specific Antibodies Therapy Market Perspective (2019-2030)

2.2 Bi-Specific Antibodies Therapy Growth Trends by Region

2.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Bi-Specific Antibodies Therapy Historic Market Size by Region (2019-2024)

2.2.3 Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2025-2030)

2.3 Bi-Specific Antibodies Therapy Market Dynamics

2.3.1 Bi-Specific Antibodies Therapy Industry Trends

2.3.2 Bi-Specific Antibodies Therapy Market Drivers

2.3.3 Bi-Specific Antibodies Therapy Market Challenges

2.3.4 Bi-Specific Antibodies Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue

3.1.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue (2019-2024)

3.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2019-2024)

3.2 Global Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Bi-Specific Antibodies Therapy Revenue

3.4 Global Bi-Specific Antibodies Therapy Market Concentration Ratio

3.4.1 Global Bi-Specific Antibodies Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Bi-Specific Antibodies Therapy Revenue in 2023

3.5 Bi-Specific Antibodies Therapy Key Players Head office and Area Served

3.6 Key Players Bi-Specific Antibodies Therapy Product Solution and Service

3.7 Date of Enter into Bi-Specific Antibodies Therapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Bi-Specific Antibodies Therapy Breakdown Data by Type

4.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Type (2019-2024)

4.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2025-2030)

5 Bi-Specific Antibodies Therapy Breakdown Data by Application

5.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Application (2019-2024)

5.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Bi-Specific Antibodies Therapy Market Size (2019-2030)

6.2 North America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)

6.4 North America Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Bi-Specific Antibodies Therapy Market Size (2019-2030)

7.2 Europe Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)

7.4 Europe Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size (2019-2030)

8.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2019-2024)

8.4 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Bi-Specific Antibodies Therapy Market Size (2019-2030)

9.2 Latin America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)

9.4 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size (2019-2030)

10.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)

10.4 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Detail

11.1.2 Roche Business Overview

11.1.3 Roche Bi-Specific Antibodies Therapy Introduction

11.1.4 Roche Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.1.5 Roche Recent Development

11.2 Amgen

11.2.1 Amgen Company Detail

11.2.2 Amgen Business Overview

11.2.3 Amgen Bi-Specific Antibodies Therapy Introduction

11.2.4 Amgen Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.2.5 Amgen Recent Development

11.3 Sanofi

11.3.1 Sanofi Company Detail

11.3.2 Sanofi Business Overview

11.3.3 Sanofi Bi-Specific Antibodies Therapy Introduction

11.3.4 Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.3.5 Sanofi Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Detail

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Bi-Specific Antibodies Therapy Introduction

11.4.4 Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.4.5 Pfizer Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Detail

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Introduction

11.5.4 Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.5.5 Johnson & Johnson Recent Development

11.6 AstraZeneca

11.6.1 AstraZeneca Company Detail

11.6.2 AstraZeneca Business Overview

11.6.3 AstraZeneca Bi-Specific Antibodies Therapy Introduction

11.6.4 AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.6.5 AstraZeneca Recent Development

11.7 AbbVie

11.7.1 AbbVie Company Detail

11.7.2 AbbVie Business Overview

11.7.3 AbbVie Bi-Specific Antibodies Therapy Introduction

11.7.4 AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.7.5 AbbVie Recent Development

11.8 Lindis Biotech

11.8.1 Lindis Biotech Company Detail

11.8.2 Lindis Biotech Business Overview

11.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Introduction

11.8.4 Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.8.5 Lindis Biotech Recent Development

11.9 MacroGenics, Inc

11.9.1 MacroGenics, Inc Company Detail

11.9.2 MacroGenics, Inc Business Overview

11.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Introduction

11.9.4 MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.9.5 MacroGenics, Inc Recent Development

11.10 Genmab

11.10.1 Genmab Company Detail

11.10.2 Genmab Business Overview

11.10.3 Genmab Bi-Specific Antibodies Therapy Introduction

11.10.4 Genmab Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.10.5 Genmab Recent Development

11.11 Alphamab Co. Ltd

11.11.1 Alphamab Co. Ltd Company Detail

11.11.2 Alphamab Co. Ltd Business Overview

11.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Introduction

11.11.4 Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.11.5 Alphamab Co. Ltd Recent Development

11.12 Akeso, Inc.

11.12.1 Akeso, Inc. Company Detail

11.12.2 Akeso, Inc. Business Overview

11.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Introduction

11.12.4 Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)

11.12.5 Akeso, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Fragment-Based Antibodies

Table 3. Key Players of IgG-Based Antibodies

Table 4. Global Bi-Specific Antibodies Therapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Bi-Specific Antibodies Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Bi-Specific Antibodies Therapy Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Bi-Specific Antibodies Therapy Market Share by Region (2019-2024)

Table 8. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Bi-Specific Antibodies Therapy Market Share by Region (2025-2030)

Table 10. Bi-Specific Antibodies Therapy Market Trends

Table 11. Bi-Specific Antibodies Therapy Market Drivers

Table 12. Bi-Specific Antibodies Therapy Market Challenges

Table 13. Bi-Specific Antibodies Therapy Market Restraints

Table 14. Global Bi-Specific Antibodies Therapy Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Bi-Specific Antibodies Therapy Market Share by Players (2019-2024)

Table 16. Global Top Bi-Specific Antibodies Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2023)

Table 17. Ranking of Global Top Bi-Specific Antibodies Therapy Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Bi-Specific Antibodies Therapy Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Bi-Specific Antibodies Therapy Product Solution and Service

Table 21. Date of Enter into Bi-Specific Antibodies Therapy Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Bi-Specific Antibodies Therapy Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2019-2024)

Table 25. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2025-2030)

Table 27. Global Bi-Specific Antibodies Therapy Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2019-2024)

Table 29. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2025-2030)

Table 31. North America Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Bi-Specific Antibodies Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Bi-Specific Antibodies Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Bi-Specific Antibodies Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Bi-Specific Antibodies Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Bi-Specific Antibodies Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 46. Roche Company Detail

Table 47. Roche Business Overview

Table 48. Roche Bi-Specific Antibodies Therapy Product

Table 49. Roche Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 50. Roche Recent Development

Table 51. Amgen Company Detail

Table 52. Amgen Business Overview

Table 53. Amgen Bi-Specific Antibodies Therapy Product

Table 54. Amgen Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 55. Amgen Recent Development

Table 56. Sanofi Company Detail

Table 57. Sanofi Business Overview

Table 58. Sanofi Bi-Specific Antibodies Therapy Product

Table 59. Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 60. Sanofi Recent Development

Table 61. Pfizer Company Detail

Table 62. Pfizer Business Overview

Table 63. Pfizer Bi-Specific Antibodies Therapy Product

Table 64. Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 65. Pfizer Recent Development

Table 66. Johnson & Johnson Company Detail

Table 67. Johnson & Johnson Business Overview

Table 68. Johnson & Johnson Bi-Specific Antibodies Therapy Product

Table 69. Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 70. Johnson & Johnson Recent Development

Table 71. AstraZeneca Company Detail

Table 72. AstraZeneca Business Overview

Table 73. AstraZeneca Bi-Specific Antibodies Therapy Product

Table 74. AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 75. AstraZeneca Recent Development

Table 76. AbbVie Company Detail

Table 77. AbbVie Business Overview

Table 78. AbbVie Bi-Specific Antibodies Therapy Product

Table 79. AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 80. AbbVie Recent Development

Table 81. Lindis Biotech Company Detail

Table 82. Lindis Biotech Business Overview

Table 83. Lindis Biotech Bi-Specific Antibodies Therapy Product

Table 84. Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 85. Lindis Biotech Recent Development

Table 86. MacroGenics, Inc Company Detail

Table 87. MacroGenics, Inc Business Overview

Table 88. MacroGenics, Inc Bi-Specific Antibodies Therapy Product

Table 89. MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 90. MacroGenics, Inc Recent Development

Table 91. Genmab Company Detail

Table 92. Genmab Business Overview

Table 93. Genmab Bi-Specific Antibodies Therapy Product

Table 94. Genmab Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 95. Genmab Recent Development

Table 96. Alphamab Co. Ltd Company Detail

Table 97. Alphamab Co. Ltd Business Overview

Table 98. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product

Table 99. Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 100. Alphamab Co. Ltd Recent Development

Table 101. Akeso, Inc. Company Detail

Table 102. Akeso, Inc. Business Overview

Table 103. Akeso, Inc. Bi-Specific Antibodies Therapy Product

Table 104. Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2019-2024) & (US$ Million)

Table 105. Akeso, Inc. Recent Development

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Bi-Specific Antibodies Therapy Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Bi-Specific Antibodies Therapy Market Share by Type: 2023 VS 2030

Figure 3. Fragment-Based Antibodies Features

Figure 4. IgG-Based Antibodies Features

Figure 5. Global Bi-Specific Antibodies Therapy Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Bi-Specific Antibodies Therapy Market Share by Application: 2023 VS 2030

Figure 7. Cancer Case Studies

Figure 8. Haemophilia Case Studies

Figure 9. Other Non-Cancer Diseases Case Studies

Figure 10. Bi-Specific Antibodies Therapy Report Years Considered

Figure 11. Global Bi-Specific Antibodies Therapy Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Bi-Specific Antibodies Therapy Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Bi-Specific Antibodies Therapy Market Share by Region: 2023 VS 2030

Figure 14. Global Bi-Specific Antibodies Therapy Market Share by Players in 2023

Figure 15. Global Top Bi-Specific Antibodies Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Bi-Specific Antibodies Therapy Revenue in 2023

Figure 17. North America Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Bi-Specific Antibodies Therapy Market Share by Country (2019-2030)

Figure 19. United States Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Bi-Specific Antibodies Therapy Market Share by Country (2019-2030)

Figure 23. Germany Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Region (2019-2030)

Figure 31. China Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Bi-Specific Antibodies Therapy Market Share by Country (2019-2030)

Figure 39. Mexico Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country (2019-2030)

Figure 43. Turkey Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Bi-Specific Antibodies Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Roche Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 46. Amgen Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 47. Sanofi Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 48. Pfizer Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 49. Johnson & Johnson Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 50. AstraZeneca Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 51. AbbVie Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 52. Lindis Biotech Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 53. MacroGenics, Inc Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 54. Genmab Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 55. Alphamab Co. Ltd Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 56. Akeso, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2019-2024)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions